Propranolol HCl

  • CAT Number: A000769
  • CAS Number: 318-98-9
  • Molecular Formula: C16H21NO2.HCl
  • Molecular Weight: 295.8
  • Purity: ≥95%
Inquiry Now

<p>
<span style="color:#000000;"><span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">Propranolol HCl (CAS 318-98-9)&nbsp;is a competitive non-selective beta-adrenergic receptors inhibitor with&nbsp;<span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">antianginal, antiarrhythmic, and antihypertensive properties<span style="caret-color: rgb(34, 34, 34);">&nbsp;(IC50 of 12 nM)</span>.</span><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">&nbsp;Propranolol&nbsp;competitively antagonizes beta-adrenergic receptors, thereby inhibiting beta-adrenergic reactions, such as vasodilation, and negative chronotropic and inotropic effects.</span></span></span></span></p>

Catalog Number A000769
CAS Number 318-98-9
Synonyms

AY-64043, ICI-45520, NCS-91523

Molecular Formula

C16H21NO2.HCl

Purity 95%
Target Adrenergic Receptor
Solubility >12.4mg/mL in DMSO
Storage 3 years -20C powder
IUPAC Name 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;hydrochloride
InChI InChI=1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H
InChIKey ZMRUPTIKESYGQW-UHFFFAOYSA-N
SMILES CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O.Cl
Reference

<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">1. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338. doi: 10.1016/bs.podrm.2017.02.006. Epub 2017 Apr 6.Propranolol.Al-Majed AA(1), Bakheit AHH(2), Abdel Aziz HA(3), Alajmi FM(1), AlRabiah H(1).</span></span></div>
<div>
&nbsp;</div>
<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">Propranolol is a noncardioselective &beta;-blocker. It is reported to have membrane-stabilizing properties, but it does not own intrinsic sympathomimetic activity. Propranolol hydrochloride is used to control hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy. It is also used to control symptoms of sympathetic overactivity in the management of hyperthyroidism, anxiety&nbsp;</span></span><span style="font-family: arial, helvetica, sans-serif;">disorders, and tremor. Other indications cover the prophylaxis of migraine and of upper gastrointestinal bleeding in patients with portal hypertension. This study provides a detailed, comprehensive profile of propranolol, including formulas, elemental analysis, and the appearance of the drug. In addition, the synthesis of the drug is described. The chapter covers the physicochemical properties, including X-ray powder diffraction, pK, solubility, melting point, and procedures of analysis (spectroscopic, electrochemical, and&nbsp;</span><span style="font-family: arial, helvetica, sans-serif;">chromatographic). In-depth pharmacology is also presented (pharmacological actions, therapeutic dosing, uses, Interactions, and adverse effects and precautions). More than 60 references are given as a proof of the abovementioned studies.</span></div>
<div>
&nbsp;</div>
<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">2. World J Emerg Surg. 2017 Mar 2;12:11. doi: 10.1186/s13017-017-0124-7. eCollection 2017.</span></span></div>
<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">Safety and effectiveness of propranolol in severely burned patients: systematic review and meta-analysis.Manzano-Nunez R(1)(2), Garc&iacute;a-Perdomo HA(2), Ferrada P(3), Ordo&ntilde;ez Delgado&nbsp;</span></span></div>
<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">CA(4), Gomez DA(2), Foianini JE(5).</span></span></div>
<div>
&nbsp;</div>
<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">BACKGROUND: The objective of this systematic review was to determine the effectiveness and safety of propranolol compared to placebo or usual care for improving clinical relevant outcomes in severely burned patients (TBSA &gt;20%).</span></span></div>
<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">METHODS: Relevant articles from randomized controlled trials were identified by a literature search in MEDLINE, EMBASE, and CENTRAL. We included trials involving patients with a severe burn (&gt;20% of total body surface area affected). Trials were eligible if they evaluated propranolol and compared to usual care or placebo. Two investigators independently assessed articles for inclusion and exclusion criteria and selected studies for the final analysis. We conducted a meta-analysis using a random-effects model.</span></span></div>
<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">RESULTS: We included ten studies in our systematic review. These studies randomized a total of 1236 participants. There were no significant differences between propranolol and placebo with respect to mortality (RD -0.02 [95% CI -0.06 to 0.02]), sepsis (RD -0.03 [95% CI -0.09 to 0.04]), and the overall hospital stay (MD -0.37 [-4.52 to 3.78]). Propranolol-treated adults had a decrease in requirements of blood transfusions (MD -185.64 [95% CI -331.06 to -40.43]) and a decreased heart rate (MD -26.85 [95% CI -39.95 to -13.75]).</span></span></div>
<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">CONCLUSIONS: Our analysis indicates that there were no differences in mortality or sepsis in severely burned patients treated with propranolol compared with those who had usual care or placebo. However, the use of propranolol in these patients resulted in lower requirements of blood transfusion and lower values of heart rate. The evidence synthesized in this systematic review is limited to conclude that propranolol reduces the length of hospital stay among severely burned patients. Future trials should assess the impact of propranolol on clinically relevant outcomes such as mortality and adverse events.</span></span></div>
<div>
&nbsp;</div>
<div>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">3. Br Med J. 1966 Nov 26;2(5525):1311-2.Propranolol.</span></span></div>
<div>
&nbsp;</div>

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!